Why to invest in SCHOTT Pharma

Global market leader in a highly attractive and protected industry

Global market leader in a highly attractive and protected industry

Pure player in injectables benefiting from healthcare megatrends

Pure player in injectables benefiting from healthcare megatrends

Strong shareholder value – high profitability and strong financials

Strong shareholder value – high profitability and strong financials

Pioneers and innovators shaping the industry since 1923

Pioneers and innovators shaping the industry since 1923

A long-term strategy with the right backing

A long-term strategy with the right backing

OUR EQUITY STORY

"

Leveraging our global position and trusted partnerships, SCHOTT Pharma is well-positioned to pursue exciting opportunities in the growing market for injectables and biologics. Our strong-margin, high-value solutions, such as prefillable syringes and ready-to-use solutions, enable us to meet the increasing demand to safely store and deliver the next generation of drugs.

 

Andreas Reisse, CEO SCHOTT Pharma

Andreas Reisse

SCHOTT Pharma in numbers (FY 2023)

m €
Revenues
m €
EBITDA
m €
CapEx
bn
Units produced p.a.
Patents

Annual Report 2022/2023 (Online)


Annual Report

Latest publications

Q1 statement / Q1 financial report 2023/2024
Thursday, February 29, 2024 | Quarterly reports
Quarterly statement Q1 2023/20...
Presentation Q1 2023/2024
Thursday, February 29, 2024 | Presentations
Presentation Q1 2023/2024
Annual financial report 2022/2023 (PDF)
Friday, January 26, 2024 | Annual reports
Annual Report 2022/2023 (PDF)
ALL PUBLICATIONS

Financial events

June 27, 2024
Half-year report (H1 2023/2024...
August 29, 2024
Quarterly statement (Q3 2023/2...
ALL EVENTS

Get in touch

Jasko Terzic (CFA)

Head of Investor Relations

If you are a journalist, please contact our Corporate Communications team.